Dynamical Characterization of Antiviral Effects in COVID-19

Pablo Abuin^a, Alejandro Anderson^a, Antonio Ferramosca^b, Esteban A. Hernandez-Vargas^c, Alejandro H. Gonzalez^a

^aInstitute of Technological Development for the Chemical Industry (INTEC), CONICET-UNL, Santa Fe, Argentina (e-mail: alejgon@santafe-conicet.gov.ar)

^bDepartment of Management, Information and Production Engineering, University of Bergamo, Via Marconi 5, 24044, Dalmine (BG), Italy (e-mail: antonio.ferramosca@unibg.it)

^c Frankfurt Institute for Advanced Studies, 60438 Frankfurt am Main, Germany (e-mail: vargas@fias.uni-frankfurt.de)

Abstract

Mathematical models describing SARS-CoV-2 dynamics and the corresponding immune responses in patients with COVID-19 can be critical to evaluate possible clinical outcomes of antiviral treatments. In this work, based on the concept of virus spreadability in the host, antiviral effectiveness thresholds are determined to establish whether or not a treatment will be able to clear the infection. In addition, the virus dynamic in the host - including the time-to-peak and the final monotonically decreasing behavior - is chracterized as a function of the treatment initial time. Simulation results, based on nine real patient data, show the potential clinical benefits of a treatment classification according to patient critical parameters. This study is aimed at paving the way for the different antivirals being developed to tackle SARS-CoV-2.

Keywords: SARS-CoV-2, In-host model, Dynamic characterization, Antiviral effectiveness.

1. Introduction

With more than 82 million cases confirmed so far (December 2020) in 213 countries [1, 2], coronavirus disease COVID-19, caused by SARS-CoV-2 virus, continues spreading around the globe without neither effective treatment or vaccine strategy. In fact, the estimated case-fatality rate (CFR) for COVID-19 is about 5.7%, while for the H1N1 pandemic the CFR was less than 1% [3].

Currently, a fully analysis about the potentiality of repurposed antiviral agents (*i.e.*, Chloroquine and Hydroxychloroquine, Remdesivir, Favipiravir, Lopinavir/Ritonavir, Ribavirin) to ameliorate the viral spreading in the host are underway [4]. The clinical observations suggest that prophylaxis with approved doses could prevent SARS-CoV-2 infection and reduce viral shedding [5, 6], but these reports suffer from a number of limitations. For instance, there is no certainty that the undefined benefits are not outweighed by the acute toxicity of the specific antiviral agents. To overcome this impasse, randomized clinical trials with adequate potency should be performed [7]. On the other hand, despite some reported dosing recommendation to treat COVID-19 [8, 9], the efficacy of these proposed therapies cannot be guaranteed due to a paucity of data regarding the optimal dose of the antivirals [10]. In a race to find medical therapies to improve outcomes in patients with COVID-19 further studies are needed to elucidate the benefits of adapting antiviral agents.

An important strategy to help to find the optimal dose of drugs is the pharmacological modelling based on in-vitro drug testing. This approach could suggest whenever the prophylaxis with an appropriate doses of antiviral agents could prevent SARS-CoV-2 infection or control the replication cycle of the virus [11]. In this regard, recent studies have concentrated on the potential of a quantitative comprehension of COVID-19 dynamics [12, 13, 14, 15]. Within-host mathematical models demonstrated useful insights about SARS-CoV-2 infection dynamics and its interactions with the immune system. More important, such results suggest the potential utility of assessing targets for drug development.

The target cell-limited model, widely used to represent several diseases such as Influenza [16, 17], Ebola [18], HIV [19, 20], Hepatitis virus [21], among others, has been linked to adjust the viral kinetics in infected patients with COVID-19 reported by [22]. While a complete analysis of the main dynamic characteristic for the target cell model was developed to evaluate SARS-CoV-2 infection [23], there is no adequate analysis of the effects of the existent pharmacological therapy for this model.

The main contribution of this work - that can be seen as an extension of [23] - is to provide a formal mathematical analysis of the COVID-19 dynamic under the effect of antiviral treatments, which may help to understand how to schedule the different therapies in function of the host parameters. A quantitative classification stating whether or not an antiviral will be effective - in terms of its capability to died out the virus in a reasonable period of time - is made, showing that their effectiveness could vary significantly between subjects.

After the introduction given in Section 1 the article is organized as follows. Section 2 proposes a general three-states "in host" model to represent COVID-19 infection dynamic and formalizes the concept of virus spreadability. Section 3 characterizes the equilibrium sets of the system, and its asymptotic stability, for the untreated case (*i.e.*, when no pharmacodynamic is considered), considering the system from the infection time t = 0. Then, in Section 4, the pharmacodynamic of antivirals is included, to analyze their effectiveness to avoid the virus to spread in the host. Both, the inhibition effect on the replication rate of the virus and the inhibition effect on the infection rate of healthy cells are studied. In Section 6, the results of Section 4 are extensively demonstrated by simulating different treatments scenarios for nine patients from the literature. Finally, Section 7 gives the discussion of the work, while several mathematical formalism - necessary to support the main results of article - are given in Appendix 8.

2. Within-Host COVID-19 infection model

Mathematical models of within-host virus dynamic helps to improve the understanding of the interactions that govern infections and permits the human intervention to moderate their effects [24]. Basic models usually include the cells the pathogen infects, the pathogen particles, and their life cycle [25] and, opposite to one can expect, they vary little in its structure from one infectious disease to another. Indeed, the well known target cell-limited models (*i.e.*, models that incorporate the immune response just as a parameter) was successfully used to represent and control HIV [26, 27, 20], influenza [28, 16, 29, 30], Ebola [18] and dengue [31, 32], among others. A main distinction between target cell models can be done according to the virus life cycle [25]: chronic infection models (long-lived and persistent virus in comparison with cells life cycle) include production and death rates of healthy/susceptible cells, while acute infection models (shortlived virus) only consider the clearance of susceptible cells produced by the infection. This latter - which was firstly introduced in [16] for the influenza - is used to describe the COVID-19, as it is detailed next.

2.1. Target-cell-limited model

In this paper we consider the following mathematical model [12, 23]:

$$U(t) = -\beta U(t)V(t), \qquad U(0) = U_0,$$
(2.1a)

$$\dot{I}(t) = \beta U(t)V(t) - \delta I(t), \qquad I(0) = I_0 = 0,$$
(2.1b)

$$\dot{V}(t) = pI(t) - cV(t), \qquad V(0) = V_0,$$
(2.1c)

where U (*cell*), I (*cell*) and V (*copies*/*mL*) represent the uninfected cells, the infected cells, and the virus concentration. The parameter β (*mLday*⁻¹/*copies*) is the infection rate, δ (*day*⁻¹) is the death rates of I, p ((*copies*)/(*cellmL*)*day*⁻¹) is the viral replication, and c (*day*⁻¹) is the viral clearance rate. The effects of immune responses are not explicitly described in this model, but they are implicitly included in the death rate of infected cells (δ) and the clearance rate of virus (c) [16].

System (2.1) is positive, which means that $U(t) \ge 0$, $I(t) \ge 0$ and $V(t) \ge 0$, for all $t \ge 0$. We denote x(t) := (U(t), I(t), V(t)) the state vector, and

$$\mathbb{X} := \{ x \in \mathbb{R}^3_{>0} \},\tag{2.2}$$

the state constraints set. Another meaningful set (which is open) is the one consisting in all the states in X with strictly positive amount of virus and susceptible cells, *i.e.*,

$$\mathcal{X} := \{ x \in \mathbb{X} : U > 0, \ V > 0 \}.$$
(2.3)

The initial conditions of (2.1), which represent a healthy steady state before the infection, are assumed to be V(t) = 0, I(t) = 0, and $U(t) = U_0 > 0$, for t < 0. Then, at time t = 0, a small quantity of virions enters the host body and, so, a discontinuity occurs in V(t). Indeed, V(t) jumps from 0 to a small positive

value V_0 at t = 0 (formally, V(t) has a discontinuity of the first kind at t_0 , *i.e.*, $\lim_{t\to 0^-} V(t) = 0$ while $\lim_{t\to 0^+} V(t) = V_0 > 0$). This way, for the time after the infection, the virus may spread or being clear depending on its infection effectiveness. To properly determine what such a spread means, the following (mathematical) definition is given

Definition 1 (Spreadability of the virus in the host). Consider system (2.1), constrained by the positive set \mathbb{X} , with V(t) = 0, I(t) = 0, and $U(t) = U_0 > 0$, for t < 0. Consider also that at time t = 0, V(t) jumps from 0 to a small positive value V_0 . Then, it is said that the virus spreads (in some degree) in the host for $t \ge 0$ if $\dot{V}(t) > 0$ for some t > 0. If the virus does not spread in the host, it is said that it is cleared for $t \ge 0$.

Definition 1 states that the virus spreads in the host, for $t \ge 0$, if V(t) increases at some time t > 0, and so, given that $\lim_{t\to\infty} V(t) = 0$ (as it is stated later on in the article), it reaches at least one local maximum at some positive time. On the other hand, the virus is cleared for $t \ge 0$ if V(t) is strictly decreasing for all t > 0, which means that V(t) has neither local minima nor local maxima at any t > 0 (latter on it is stated that V(t) has at most one minimum and one maximum). An infectious disease can be related to the virus peak and/or the period of permanence of the virus in the host [18], and both effects are related to an increase of the virus load at some time after the infection. This is the reason why the spreadability is defined based on the virus positive derivative. A second reason supporting Definition 1 is its use in the determination of antiviral effectiveness (Section 4). Antivirals able to clear the virus can be considered effective.

Remark 1. Note that the virus spreadability may or may not imply a severe infection (a disease that eventually causes the host symptoms) depending on the value of the virus peak and the time the virus remains in the host. The non-spreadability of the virus, however, does imply that the infection is controlled.

In what follows, time t = 0 will be considered as the infection time, *i.e.*, the time when a small amount of virus enters the host.

2.2. Reproduction number and critical value for the target cells

To formally establish conditions under which the virus does or does not spread for t > 0, some basic concepts need to be defined. The first one is the well-known basic reproduction number.

Definition 2. The within-host basic reproduction number \mathcal{R} is defined as the number of infected cells (or virus particles) that are produced by one infected cell (or virus particle), over a course of its life-span. Its mathematical expression is given by:

$$\mathcal{R}(t) := U(t) \frac{\beta p}{c\delta}.$$
(2.4)

Particularly, for t = 0, this number describes the number of virus particles produced by a virus particle when a small amount of virus, V_0 , is introduced into a healthy stationary population of uninfected target cells, U_0 ,

$$\mathcal{R}_0 := U_0 \frac{\beta p}{c\delta}.$$
(2.5)

A second number, which is closely related to the first one, is the critical value for the susceptible cells such that the virus starts to decrease.

Definition 3. The critical number of susceptible cells U, U_c , is defined as

$$\mathcal{U}_c := \frac{c\delta}{p\beta},\tag{2.6}$$

which for fixed system parameters β , p, δ and c is a constant.

Note that $U(t) < U_c$ if and only if $\mathcal{R}(t) < 1$, for every $t \ge 0$. The basic reproduction number $\mathcal{R}(t)$ and the critical number U_c completely describe dynamic (2.1), as it is shown in the next sections.

3. Dynamical analysis for the untreated infection

In this section, the infection evolution from the beginning (time t = 0) is considered without antiviral treatments. A detailed analysis of the dynamical behaviour will help us to properly understand, in next sections, the antivirals effects.

3.1. Equilibrium set characterization and stability

By equaling U, I and V to zero, in (2.1), it can be shown that the system only has free virus equilibrium of the form $x_s = (U_s, 0, 0)$, with U_s being an arbitrary positive value, *i.e.*, $U_s \in [0, \infty)$. Thus, there is only one equilibrium set, which is a healthy one, and it is defined by

$$\mathcal{X}_s := \{ (U, I, V) \in \mathbb{R}^3 : U \in [0, \infty), \ I = 0, \ V = 0 \}.$$
(3.1)

According to [23], set \mathcal{X}_s can be partitioned in two subsets,

$$\mathcal{X}_{s}^{1} := \{ (U, I, V) \in \mathbb{R}^{3} : U \in [0, \mathcal{U}_{c}), \ I = 0, \ V = 0 \}$$
(3.2)

and

$$\mathcal{X}_{s}^{2} := \{ (U, I, V) \in \mathbb{R}^{3} : U \in [\mathcal{U}_{c}, \infty), \ I = 0, \ V = 0 \}$$
(3.3)

being \mathcal{X}_s^1 asymptotically stable and \mathcal{X}_s^2 unstable, as stated in the next theorem.

Theorem 3.1 (Asymptotic stability). Consider system (2.1) constrained by the positive set X. Then, the set \mathcal{X}_s^1 defined in (3.2) is the smallest asymptotically stable (AS) equilibrium set, with a domain of attraction given by \mathcal{X} .

Proof: The proof is given in [23], Theorem 3.3. \Box

Theorem 3.1 establishes that neither single equilibrium points $x_s \in \mathcal{X}_s^1$ nor subsets of \mathcal{X}_s^1 are AS. Furthermore, any trajectory starting at non-equilibrium states tends to a state in \mathcal{X}_s^1 , which depends on the initial conditions. This has critical implications on the controllability of the system, provided that \mathcal{X}_s^1 is the minimal formal equilibrium target set to be used in a control strategy (based, for instance, on antiviral treatments).

Furthermore, as stated in [23], if we define $U_{\infty} = \lim_{t\to\infty} U(t)$, $I_{\infty} = \lim_{t\to\infty} I(t)$ and $V_{\infty} = \lim_{t\to\infty} V(t)$, then, $I_{\infty} = 0$, $V_{\infty} = 0$, and

$$U_{\infty} = -\mathcal{U}_c W(-\mathcal{R}_0 e^{-(\mathcal{R}_0 + \mathcal{K}_0)}), \qquad (3.4)$$

where $W(\cdot)$ is the Lambert function, and $\mathcal{R}_0 = U_0 \frac{\beta p}{c\delta}$ and $\mathcal{K}_0 = \frac{\beta}{c} (\frac{p}{\delta} I_0 - V_0)$ are constants depending on the initial conditions. Given that $W(-\mathcal{R}_0 e^{-(\mathcal{R}_0 + \mathcal{K}_0)}) \in (0, 1)$ for positive values of \mathcal{R}_0 and \mathcal{K}_0 , this means that the only state that does not necessarily converge to zero, *i.e.* U, converges to a value smaller than \mathcal{U}_c , which depends on U_0, I_0, V_0 . See [23] for further details.

3.2. System behavior

The general behavior of system (2.1) can be analyzed according to the initial conditions and parameter values. Property 1, next, shows some general characteristics of the susceptible cells as time goes to infinity ([23]).

Property 1. Consider system (2.1), constrained by the positive set X, at the beginning of the infection, i.e., $U(0) = U_0 > 0$, I(0) = 0 and $V(0) = V_0 > 0$ (i.e., $x(0) = (U(0), I(0), V(0)) \in \mathcal{X}$). Consider also that V_0 is small enough. Then,

- *i.* $U_{\infty} \to 0$ when $U_0 \to \infty$ or $U_0 \to 0$.
- ii. $U_{\infty} \rightarrow \mathcal{U}_c$ when $U_0 \rightarrow \mathcal{U}_c$.
- *iii.* $0 < U_{\infty}(U_{0,1}, I_0, V_0) < U_{\infty}(U_{0,2}, I_0, V_0) < \mathcal{U}_c$, for initial conditions $U_{0,1} < U_{0,2} < \mathcal{U}_c$.
- iv. $0 < U_{\infty}(U_{0,2}, I_0, V_0) < U_{\infty}(U_{0,1}, I_0, V_0) < \mathcal{U}_c$, for initial conditions $\mathcal{U}_c < U_{0,1} < U_{0,2}$.

Proof: The proof - which is given in [23], Property 2 - follows from the fact that $\mathcal{K}_0 \approx 0$ for the selected initial conditions, and, so, according to (3.4), $U_{\infty} \approx -\mathcal{U}_c W(-\mathcal{R}_0 e^{-\mathcal{R}_0})$.

Figure 1 shows a phase portrait of system (2.1), with parameters $\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5, which provide $U_c = 1$. As it can be seen, every initial state, even those that are close to the axes (U, 0, 0) with large values of U, tends to \mathcal{X}_s^1 as $t \to \infty$. The following theorem characterizes the whole dynamic of system (2.1) from the start of the infection, in terms of the variables peaks.

Theorem 3.2 (Virus behavior from the infection time). Consider system (2.1), constrained by the positive set \mathbb{X} , at the beginning of the infection, i.e., $U(0) = U_0 > 0$, I(0) = 0 and $V(0) = V_0 > 0$ (i.e., $x(0) = (U(0), I(0), V(0)) \in \mathcal{X}$). If the virus spreads (according to Definition 1), then $\mathcal{R}_0 > 1 + \alpha(0)$, for some $\alpha(0) > 0$ (or, the same, $U_0 > U_c$) and there exist positive times \check{t}_V , \hat{t}_I , t_c and \hat{t}_V , such that $\check{t}_V < \hat{t}_I < t_c < \hat{t}_V$, where \check{t}_V and \hat{t}_V are the times at which V(t) reaches a local minimum and a local maximum, respectively, \hat{t}_I is the time at which I(t) reaches a local maximum, and t_c is the time at which U(t) reaches \mathcal{U}_c . Furthermore, $\dot{V}(t) < 0$ for all $t > \hat{t}_V$.

Proof: The proof is given in [23], Theorem 4.1.

Remark 2. Function $\alpha(t)$, $t \ge 0$, can be thought as a correction factor of the reproduction number $\mathcal{R}(t)$, necessary to understand and characterize the threshold over which the virus spreads in the host. As it is shown in [23], Remark 5, this function cannot be explicitly defined but may be computed numerically. In general, for real patient data, it takes small values when the virus load is small (particularly, at time t = 0), and becomes significant only when the virus approaches its peak, at \hat{t}_V . Given that in most of the interesting situations (i.e., at the beginning of the infection or when an antiviral is administered before the virus peak) its effect is negligible, $\alpha(t)$ will not be considered in the computation of critical values for the treatments.

Remark 3. Note that from Theorem 3.2, it follows that a sufficient condition (not necessary) for the virus not to spread in the host at time t > 0 is given by $\mathcal{R}_0 < 1$ (or, the same, $U(0) < \mathcal{U}_c$). This condition, adapted for the time an antiviral treatments is initiated, will serve in the next section to determine their effectiveness.

Next, a Remark concerning a particularity of Theorem 3.2 is introduced, which may help to approximately determine when the maximum of the virus load occurs.

Remark 4. Consider that the assumptions of Theorem 3.2 hold. If the virus clearance is significantly faster than the infected cell death ($c >> \delta$), as it is usually the case (see [15], Equation (4), [33], [34], [35]) the three-states system (2.1) can be approximated by the following two-state equations:

$$\dot{U}(t) \approx -\beta U(t)V(t), \qquad U(0) = U_0,$$
(3.5a)

$$\dot{V}(t) \approx \frac{p\beta}{c} U(t)V(t) - \delta V(t), \qquad V(0) = V_0, \tag{3.5b}$$

where the infected cell state is given by $I(t) \approx \frac{c}{p}V(t)$. Note that equation (3.5.b) can be written as $\dot{V}(t) = (\mathcal{R}(t) - 1)\delta V(t)$. Then, according to Theorem 3.2, it is easy to see that $\hat{t}_V \to t_c$ from the right and $\hat{t}_I \to t_c$ from the left when $(c/\delta) \to \infty$, i.e., the peaks of V and I tend to occur simultaneously, at time t_c . Figure 1 shows a phase portrait of system (2.1) with a rather unrealistic parameter values ($\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5) but useful to exemplify how, after a relatively short time (and provided that $c > \delta$), the system reaches the manifold defined by the condition $I(t) = \frac{c}{p}V(t)$. This behavior can also be seen in the time-behavior plot in Figure 2.

Figure 2 shows U(t), I(t), V(t) and $\mathcal{R}(t)$ time evolution, for $\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5, and initial conditions such that $\mathcal{R}_0 > 1 + \alpha(0)$ and $\mathcal{R}_0 < 1 + \alpha(0)$ (with $\alpha(0) \approx 0$). As it can be seen, the results in Theorem 3.2 and Remarks 4 and 3 are confirmed by the simulations. All these results are also confirmed by the nine real patients identified and simulated in Section 5 and 6 (see, particularly, Table 2 and Figure 5).

4. Antiviral Treatments

The goal of this section is to formally consider the effect of antivirals into system (2.1) to obtain a controlled system, *i.e.* a system with certain control actions - given by the antivirals - that allows one



Figure 1: Phase portrait of system (2.1) with parameters $\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5, for different initial conditions not necessarily representing realistic cases. Empty circles represent the initial state, while solid circles represent final states. The red hyperplane corresponds to $U(t) \equiv U_c$ (*i.e.*, the critical value of U, when $\mathcal{R}(t) = 1$) while the blue hyperplane corresponds to the fast manifold in which I(t) and V(t) are proportional (.i.e, I(t) = c/pV(t)). Note that only the initial states with $U_0 > U_c = 1$ corresponds to scenarios with $\mathcal{R}_0 > 1$.



Figure 2: Time evolution of U(t), I(t), V(t), and $\mathcal{R}(t)$ corresponding to system (2.1), with parameters $\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5 and initial conditions $U_0 = 3$, $I_0 = 0$, $V_0 = 0.1$ (first row) and $U_0 = 0.5$, $I_0 = 0$, $V_0 = 0.1$ (second row). The firs row corresponds to the case $\mathcal{R}_0 > 1 + \alpha(0)$, while the second one corresponds to the case $\mathcal{R}_0 < 1 + \alpha(0)$ (with $\alpha(0)$ being approximately zero). In the first case, the minimum of V(t) occurs at $\tilde{t}_V = 0.85$, the maximum of I occurs at $\hat{t}_I = 14.86$, U(t) crosses 1 at $t_c = 14.87$ and the maximum of V(t) occurs at $\hat{t}_V = 15.08$, which confirms both, the results in Theorem 4.1 and Remark 4. In the second case, both I(t) and V(t) are strictly decreasing and U(t) remains almost constants, which confirms the results in Theorem 4.1 and Remark 3.

to (even partially) modified the whole system dynamic according to some control objectives. Antivirals have the potential to inhibit the virus replication, reducing the advance of the infection over the target cells of infected host (*i.e.*: epithelial cells in the respiratory tract for H1N1 [16]). Several antivirals are being tested for COVID-19 treatment, with different results concerning both, their inhibition effect on the virus replication and their toxicity. Among them, Remdesivir, Favipiravir, Umifenovir, Chloroquine, Oseltamivir, etc. [36, 10, 37, 38, 39] can be mentioned. The antiviral effect can be modeled as a reduction of the virus infectivity in the presence of inhibitors (by reducing the infection rate β) and/or as a reduction in the replication of infectious virions (by reducing the replication rate p) [4, 15]. In any case, the effectiveness of a treatment is limited and depends on the patient parameters (which in turn depends on his/her clinical state). Next, two different inhibition effects $\eta_{\beta}(t)$ and $\eta_{p}(t)$ are considered, one affecting the infection rate β and the other affecting the replication rate p. It is assumed that the virus spreads in the host from the infection time t = 0, *i.e.*, V(t) reaches a maximum at some time \hat{t}_{V} if no treatment is initiated. The controlled system (*i.e.*, the system considering antiviral treatment) can be written as:

$$U(t) = -\beta(1 - \eta_{\beta}(t))U(t)V(t), \qquad U(0) = U_0, \qquad (4.1a)$$

$$\dot{I}(t) = \beta (1 - \eta_{\beta}(t))U(t)V(t) - \delta I(t), \qquad I(0) = I_0, \qquad (4.1b)$$

$$\dot{V}(t) = p(1 - \eta_p(t))I(t) - cV(t),$$
 $V(0) = V_0,$ (4.1c)

where $\eta_{\beta}(t) \in [0, 1)$ and $\eta_{p}(t) \in [0, 1)$ are assumed to jump from 0 to the new value η_{β} and η_{p} at the treatment time t_{tr} (*i.e.*, the pharmacokinetic of the antivirals is assumed to have time constants significantly smaller than the ones of system (2.1), and, so, it is neglected)

$$\eta_{\beta}(t) = \begin{cases} 0 & t < t_{tr} \\ \eta_{\beta} & t \ge t_{tr} \end{cases}, \quad \eta_{p}(t) = \begin{cases} 0 & t < t_{tr} \\ \eta_{p} & t \ge t_{tr} \end{cases},$$
(4.2)

being $\eta_{\beta} \in [0,1)$ and $\eta_{p} \in [0,1)$ constant values representing the full inhibition treatment effect. The treatment time t_{tr} is assumed to be between the minimum and maximum time of V, *i.e.*, $\check{t}_{V} < t_{tr} < \hat{t}_{V}$ (although some simulations are performed for $t_{tr} > \hat{t}_{V}$). The full antiviral effect η_{p} and η_{β} are limited by the inhibitory potential of the drug (expressed in terms of EC₅₀, or drug concentration for inhibiting 50% of antigen particles) and its cytotoxic effect (expressed in terms of IC₅₀, or drug concentration which causes death to 50% of susceptible cells) [38, 40].

As the antiviral treatment reduces the system parameter in some amount, it will quantitatively modify the virus behavior. Particularly, the virus peak time will be modified from \hat{t}_V (untreated patient case) to $\hat{t}_{V,tr}$ (treated patient case). However, given that the treatment is initiated when the virus is increasing (*i.e.*, between \check{t}_V and \hat{t}_V), then the new peak will occur at the same time or after the treatment time, *i.e.*, $\hat{t}_{V,tr} \ge t_{tr}$. This way, even when the virus peak will always be smaller with a treatment (smaller peaks are obtained for smaller values of p and β), the time at which this peak takes place can be smaller or greater than the one without any treatment. This effect, usually disregarded in many studies concerning the effectiveness of antivirals, could be critical to define whether or not a given antiviral is able to impede a severe disease. Indeed, in some cases, antivirals significantly delay the virus peaks, largely increasing the time of permanence of the virus in the host. In order to qualitatively assess antiviral effectiveness according to the time of the virus peak, the following classification is made:

Definition 4 (Antiviral treatment effectiveness). Consider system (4.1), constrained by the positive set X, such that the virus spreads in the host from time t = 0, which implies that: $U(0) > U_c$, I(0) = 0 and V(0) > 0. Consider also that, at time t_{tr} , with $\check{t}_V < t_{tr} < \hat{t}_V$, an antiviral treatment is initiated such that $\eta_p(t)$ and/or $\eta_\beta(t)$ jump from 0 to $\eta_p \in [0, 1)$ and/or $\eta_\beta \in [0, 1)$, respectively (as stated in (4.2)). Then, the treatment is said to be effective if the virus peaks at a time $\hat{t}_{V,tr} < \hat{t}_V$, being the latter the virus peak time for the untreated virus evolution (i.e., when $\eta_p = \eta_\beta = 0$). Otherwise, if $\hat{t}_{V,tr} \ge \hat{t}_V$, it is said that the treatment is ineffective.

Definition 4 is closely related to the capacity of the antiviral drug to clear the virus infection (or, the same, cutting off its spread) in such a way that it could: a) decline the viral grow at the treatment time, and, so, the virus eradication starts when the therapy is initiated, or b) hasten the virus peak, and, so, even though the virus eradication is not started at treatment time, it begins prior to the untreated case. Note also that Definition 4 accounts for three typical antiviral effect metrics: the area under the virus curve (AUC) and the duration of infection (DI) [41], in a direct way, and the difference of viral loads at the time-to-peak ΔV [13], in an indirect way.

4.1. Antiviral effectiveness characterization

In this subsection it is shown that the effectiveness of antivirals depends on weather η_p and/or η_β are greater or smaller than a specified threshold, which is a function of the parameters and the time of the treatment initiation. In order to characterize such thresholds, the within-host basic reproduction number \mathcal{R} at treatment time t_{tr} is computed as follows:

$$\mathcal{R}(t_{tr}) = \frac{U(t_{tr})p(1-\eta_p)\beta(1-\eta_\beta)}{c\delta},\tag{4.3}$$

where $\check{t}_V < t_{tr} < \hat{t}_V$. The critical values of η_p and η_β are the ones that make $\mathcal{R}(t_{tr}) = 1$, *i.e.*:

$$\eta_p^c(t_{tr}) := 1 - \frac{c\delta}{U(t_{tr})\beta p}$$
(4.4)

$$\eta_{\beta}^{c}(t_{tr}) := 1 - \frac{c\delta}{U(t_{tr})\beta p} = \eta_{p}^{c}(t_{tr}).$$
(4.5)

From equations 4.4 and 4.5 it can be inferred that $\eta_p^c(t_{tr})$ and $\eta_\beta^c(t_{tr})$ are increasing functions of $U(t_{tr})$. Figure 3 shows the time behavior of $\eta_p^c(t_{tr})$ for the nine COVID-19 patients identified in Section 5. Note that $\eta_p^c(t_{tr}) \approx 1 - c\delta/(U_0\beta p)$ for $t_{tr} \to t_0$ and $\eta_p^c(t_{tr}) \approx 1 - c\delta/(U_c\beta p) = 0$ for $t_{tr} \to \hat{t}_V$ ($t_c \approx \hat{t}_V$). Similar results concerning the critical drug efficacy with respect to the availability of target cells at the treatment time were reached in [42], for acute models, although the authors focused the analysis on treatment starting at the beginning of the infection.



Figure 3: $\eta_n^c(t_{tr})$ vs t_{tr} corresponding to the nine patients simulated in Section 5

The following theorem determines the effectiveness of antivirals in terms of $\eta_p^c(t_{tr})$ and $\eta_\beta^c(t_{tr})$, by considering them separately. In the next subsection, the combined effect will be studied.

Theorem 4.1. Consider system (4.1), constrained by the positive set X. Consider that the virus spreads in the host for $t \ge 0$, which implies that: $U(0) > \mathcal{U}_c$, I(0) = 0 and V(0) > 0. Consider also that, at time t_{tr} , with $\check{t}_V < t_{tr} < \hat{t}_V$ (when the virus is increasing), an antiviral treatment is initiated such that $\eta_p(t)$ or $\eta_\beta(t)$ jumps from 0 to $\eta_p \in [0, 1)$ or $\eta_\beta \in [0, 1)$, respectively (as stated in (4.2)). Then,

- *i.* if the inhibition effect is such that $\eta_p > \eta_p^c(t_{tr})$ (or $\eta_\beta > \eta_\beta^c(t_{tr})$) then the maximum of V(t) occurs at t_{tr} , which is smaller than \hat{t}_V by hypothesis. In this case **the antiviral treatment is effective**.
- *ii.* for two antiviral treatment, 1 and 2, with inhibition effects η_p^1, η_p^2 such that $\eta_p^c(t_{tr}) < \eta_p^1 < \eta_p^2$ (or two inhibition effects $\eta_\beta^1, \eta_\beta^2$ such that $\eta_\beta^c(t_{tr}) < \eta_\beta^1 < \eta_\beta^2$), there exist a time $t^* > t_{tr}$ (large enough) such

that $V_2(t) < V_1(t)$, for all $t \in (t_{tr}, t^*]$, being $V_1(t)$ and $V_2(t)$ the virus corresponding to treatments η_p^1 and η_p^2 , respectively. In this case both treatments are effective, and treatment 2 is more efficient than treatment 1.

- iii. if the inhibition effect is such that $\eta_p < \eta_p^c(t_{tr})$ (or $\eta_\beta < \eta_\beta^c(t_{tr})$), then the virus reaches a maximum at a time $\hat{t}_{V,tr} > t_{tr}$. Furthermore, there exists a time $t^e = t^e(\eta_p, t_{tr})$ denoted as early treatment time such that $\hat{t}_{V,tr} > \hat{t}_V$ for $t_{tr} \in (\check{t}_V, t^e]$. In this case the antiviral treatment is ineffective.
- iv. for two antiviral treatment, 1 and 2, with inhibition effects η_p^1, η_p^2 such that $\eta_p^1 < \eta_p^2 < \eta_p^c(t_{tr})$ with $t_{tr} \in (\check{t}_V, t^e(\eta_p, t_{tr})]$ (or for two inhibition effects $\eta_\beta^1, \eta_\beta^2$ such that $\eta_\beta^1 < \eta_\beta^2 < \eta_\beta^c(t_{tr})$), it is $\hat{t}_{V,tr}^2 > \hat{t}_{V,tr}^1 > \hat{t}_V$, being $\hat{t}_{V,tr}^1$ and $\hat{t}_{V,tr}^2$ the virus maximum time corresponding to treatments η_p^1 and η_p^2 , respectively. In this case both treatments are ineffective, but treatment 1 is more efficient than treatment 2, which is a rather counter-intuitive fact.

Sketch of Proof: For the sake of simplicity and clarity the proof is based on the approximation of system (2.1) described in Remark 4. In such a case, system (2.1) is approximated by $\dot{U}(t) = -\beta U(t)V(t)$, $\dot{V}(t) \approx (\mathcal{R}(t) - 1)\delta V(t)$ and $I(t) \approx \frac{c}{p}V(t)$. Only antiviral treatments affecting parameter p is considered, since the results follows from conditions on $\mathcal{R}(t)$ and parameters β and p affect \mathcal{R} in the same way.

- i. Since $\check{t}_V < t_{tr} < \hat{t}_V$ (by hypothesis) and $\hat{t}_V \approx t_c$, then by Theorem 3.2, $\mathcal{R}(t) > 1$ for $t < t_{tr}$. Given that $\eta_p > \eta_p^c(t_{tr})$, then by (4.3) $\mathcal{R}(t)$ jumps to a value smaller than one at t_{tr} , *i.e.*, $\mathcal{R}(t_{tr}^-) > 1$ and $\mathcal{R}(t_{tr}) < 1$ (where $\mathcal{R}(t_{tr}^-) := \lim_{t \to t_{tr}^-} \mathcal{R}(t)$). Given that U(t) is strictly decreasing, $\mathcal{R}(t) < 1$ for $t > t_{tr}$. From equation $\dot{V}(t) \approx (\mathcal{R}(t) 1)\delta V(t)$, it follows that $\dot{V}(t) < 0$ for all $t > t_{tr}$. So, given that is assumed that V(t) is increasing when the treatment is initiated, its maximum occurs at t_{tr} .
- ii. Let us consider that for all $t \ge t_{tr}$, $V_i(t)$ and $U_i(t)$ are the virus and the susceptible cells for treatment i = 1, 2, i.e., the treatment under the inhibition effect η_p^i , and $\mathcal{R}_i(t) = \frac{U_i(t)(1-\eta_p^i)p\beta}{c\delta}$ with $U_1(t_{tr}) = U_2(t_{tr})$ and $V_1(t_{tr}) = V_2(t_{tr})$. By hypothesis $\eta_p^c(t_{tr}) < \eta_p^1 < \eta_p^2$, then $\mathcal{R}_2(t_{tr}) < \mathcal{R}_1(t_{tr})$ and $\mathcal{R}_i(t) < 1$ for all $t \ge t_{tr}$ and i = 1, 2. Since $U_i(t)$ is a continuous function for i = 1, 2, there is a positive time $t^* > t_{tr}$ such that $\mathcal{R}_2(t) < \mathcal{R}_1(t)$ for all $t \in [t_{tr}, t^*]$. From equation $V_i(t) \approx (\mathcal{R}_i(t) 1)\delta V_i(t)$ it follows that $V_2(t) < V_1(t) < 0$ for all $t \in (t_{tr}, t^*]$ (note that V is not defined on t_{tr}). As it is shown in Section 6.1, for real data patients, t^* is large enough such that $V(t^*) \approx 0$.
- iii. Since $\check{t}_V < t_{tr} < \hat{t}_V$ (by hypothesis) and $\hat{t}_V \approx t_c$, then by Theorem 3.2, $\mathcal{R}(t) > 1$ for $t < t_{tr}$. Given that $\eta_p < \eta_p^c(t_{tr})$, then by (4.3) $\mathcal{R}(t)$ jumps, at t_{tr} , from $\mathcal{R}(t_{tr}^-) = \frac{U(t_{tr})p\beta}{c\delta}$ to the smaller value $\mathcal{R}(t_{tr}) = \frac{U(t_{tr})p(1-\eta_p)\beta}{c\delta}$, which is still greater than one; *i.e.*, $\mathcal{R}(t_{tr}^-) > \mathcal{R}(t_{tr}) > 1$. From the fact that $\mathcal{R}(t_{tr}) > 1$, it follows that $\dot{V}(t_{tr}) > 0$, and given that $\mathcal{R}(t)$ is decreasing for $t > t_{tr}$, there exists a time $\hat{t}_{V,tr} > t_{tr}$ such that $\mathcal{R}(\hat{t}_{V,tr}) = 1$, in which case, it is

$$\dot{V}(\hat{t}_{V,tr}) \approx (\mathcal{R}(\hat{t}_{V,tr}) - 1)\delta V(\hat{t}_{V,tr}) = 0,$$
(4.6)

$$\ddot{V}(\hat{t}_{V,tr}) \approx -\frac{p\beta^2}{c} U(\hat{t}_{V,tr}) V(\hat{t}_{V,tr}) + (\mathcal{R}(\hat{t}_{V,tr}) - 1)^2 \delta^2 V(\hat{t}_{V,tr}) < 0.$$
(4.7)

This means that V(t) reaches a maximum at time $\hat{t}_{V,tr} > t_{tr}$. Now, we need to prove that there exist a time $t^e(\eta_p, t_{tr})$ such that for $t_{tr} \in (\check{t}_V, t^e)$ it is $\hat{t}_{V,tr} > \hat{t}_V$. According to Lemma 1, there exists a time $t^e = t^e(\eta_p, t_{tr})$, smaller than \hat{t}_V , such that for a treatment time $t_{tr} \in (\check{t}_V, t^e]$, $\hat{t}_{V,tr}$ is a decreasing function of $\mathcal{R}(t_{tr})$, for $\mathcal{R}(t_{tr}) > 1$. This implies that smaller values of $\mathcal{R}(t_{tr})$ (greater values of η_p) correspond to larger times at which $\mathcal{R}(t)$, $t > t_{tr}$, reaches 1, *i.e.*, smaller values of $\mathcal{R}(t_{tr})$, correspond to larger values of $\hat{t}_{V,tr}$. So, from the fact that $\mathcal{R}(t_{tr}) > \mathcal{R}(t_{tr})$ (being $\mathcal{R}(t_{tr})$) the value of \mathcal{R} at t_{tr} if no treatment is applied), it follows that $\hat{t}_{V,tr} > \hat{t}_V > t_{tr}$, for $t_{tr} \in (\check{t}_V, t^e]$. As it is shown in Sections 6.1 and 6.2, for real data patients, (the maximal) t^e is close to \hat{t}_V .

iv. Since $\eta_p^1 < \eta_p^2 < \eta_p^c(t_{tr})$, by hypothesis, then $1 < \mathcal{R}_2(t_{tr}) < \mathcal{R}_1(t_{tr})$, being $\mathcal{R}_1(t_{tr}) = \frac{U(t_{tr})p(1-\eta_p^1)\beta}{c\delta}$ and $\mathcal{R}_2(t_{tr}) = \frac{U(t_{tr})p(1-\eta_p^2)\beta}{c\delta}$. Therefore, by following the same steps of the previous item, it follows that $\hat{t}_{V,tr}^2 > \hat{t}_{V,tr} > \hat{t}_V$, being $\hat{t}_{V,tr}^1$ and $\hat{t}_{V,tr}^2$ the maximum times of the virus corresponding to η_p^1 and η_p^2 , respectively. \Box

Remark 5. According to Theorem 3.2, $\mathcal{R}(t_{tr})$ should be compared to $1 + \alpha(t_{tr})$, not to 1, to obtain $\eta_p^c(t_{tr})$ and $\eta_\beta^c(t_{tr})$. However, as stated in Remark 2, the correction factor $\alpha(t_{tr})$ is significantly smaller than 1 for the considered period of time (when t_{tr} is smaller than \hat{t}_V), so it was disregarded for the sake of simplicity. The effect of $\alpha(t_{tr})$ may be significant only for t_{tr} close to \hat{t}_V and, in such case, the viral dynamic can be slightly different from the one prescribed by Theorem 4.1 (and Lemma 1).

Remark 6. Item (iii) of Theorem 4.1 establishes just the existence of $t^e > \check{t}_V$ such that for treatments starting at $t_{tr} \in (\check{t}_V, t^e]$, the new virus peak time is larger than the one corresponding to the untreated case, i.e., $\hat{t}_{V,tr} > \hat{t}_V$. However, it should be noted that for parameters coming from real patient data, (the maximal) t^e is indeed close to \hat{t}_V . This means that the time period where treatments can be ineffective is in most of the cases similar to (\check{t}_V, \hat{t}_V) , i.e., similar to the time period where the virus is growing. Figures in Section 6 confirm this fact.

A main consequence of item (*iii*) of Theorem 4.1 is that early treatments, if no effective, are largely more dangerous than late ones. Another critical point to be remarked is that when an early treatment is not strong enough to avoid the virus spreadability right after t_{tr} , the greater the antiviral effectiveness η_p (or η_β) is, the more is the time the virus remains in the host, since the maximum time $\hat{t}_{V,tr}$ is delayed, as established in item (iv). As a result, antivirals could be detrimental as treated patients would need to be isolated for larger periods of time than untreated ones.

Note that even when virus peak time can be delayed for some treatments, the virus peak will be always smaller than the one without any treatment. Furthermore, the fraction of dead cells at the end of the infection (D) will be always greater if no antiviral is administrated. Since $D = 1 - U_{\infty}/U(t_{tr})$, if we consider initial conditions at treatment time in equation 3.4, and being $U_c^{tr} = U(t_{tr})/R(t_{tr})$, it results

$$D = 1 + \frac{W(-\mathcal{R}(t_{tr})e^{-(\mathcal{R}(t_{tr}) + \mathcal{K}(t_{tr})))})}{\mathcal{R}(t_{tr})},$$
(4.8)

where $\mathcal{K}(t_{tr}) = \frac{\beta}{c} \left(\frac{p(1-\eta_p)}{\delta} I(t_{tr}) - V(t_{tr}) \right) = \mathcal{R}(t_{tr}) I(t_{tr}) - \frac{\beta}{c} V(t_{tr})$ and $W(\cdot)$ is the Lambert function $(W(\cdot) = W_p(\cdot)$, see [23]). Consequently, if treatment is started early, such that $\mathcal{R}(t_{tr}) \gg \mathcal{K}(t_{tr})$, then the fraction of dead cells can be approximated as $D = 1 + \frac{W(-\mathcal{R}(t_{tr})e^{-\mathcal{R}(t_{tr})})}{\mathcal{R}(t_{tr})}$, which is equal to 0 if $R(t_{tr}) \leq 1$. Note that, by definition, $W(-\mathcal{R}(t_{tr})e^{-\mathcal{R}(t_{tr})}) = -\mathcal{R}(t_{tr})$ for $R(t_{tr}) \leq 1$, so $D = 1 + (-\mathcal{R}(t_{tr})/\mathcal{R}(t_{tr})) = 0$. On the other hand, if $\mathcal{R}(t_{tr}) > 1$ then $W(-\mathcal{R}(t_{tr})e^{-\mathcal{R}(t_{tr})}) \in (-1, 0]$ is monotonically increasing with $\mathcal{R}(t_{tr})$ (see Figure 1, [23]). Hence, the fraction of dead cells at the end of infection is a monotonically increasing function of $\mathcal{R}(t_{tr})$, for $\mathcal{R}(t_{tr}) > 1$. Moreover, as the treatment time is delayed, $\mathcal{K}(t_{tr})$ grows, being D a monotonically increasing function of $\mathcal{R}(t_{tr})$, even for $\mathcal{R}(t_{tr}) \leq 1$.

4.2. Antiviral effectiveness considering the combined effect on η_{β} and η_{p}

Theorem 4.1 describes the behavior of the virus under the effect of an inhibitor reducing the infection rate β or the replication rate p. If both effects (η_{β} and η_{p}) are simultaneously included in the model, it can be computed a region - in the η_{β} , η_{p} space - for which condition $\mathcal{R}(t_{tr}) < 1$ is fulfilled. This way, instead of independent critical values $\eta_{\beta}^{c}(t_{tr})$ and $\eta_{p}^{c}(t_{tr})$ corresponding to each parameter, there is an entire set of critical combinations that makes a treatment effective. This set depends on treatment time t_{tr} and is placed on the boundary of the effective set

$$\mathcal{H}^{c}(t_{tr}) := \{ (\eta_{\beta}, \eta_{p}) \in [0, 1] \times [0, 1] : \eta_{p} > 1 - \frac{c\delta}{U(t_{tr})\beta p(1 - \eta_{\beta})} \}.$$
(4.9)

Clearly, every pair $(\eta_{\beta}, \eta_p) \in \mathcal{H}^c(t_{tr})$ fulfills condition $\mathcal{R}(t_{tr}) < 1$ and, reciprocally, every pair $(\eta_{\beta}, \eta_p) \notin \mathcal{H}^c(t_{tr})$ fulfills condition $\mathcal{R}(t_{tr}) > 1$. Figure 4 shows a plot of set $\mathcal{H}^c(t_{tr})$ in the plane $(\eta_{\beta} \times \eta_p)$, corresponding to parameters $\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5, with $U(t_{tr}) = 3$.



Figure 4: $\mathcal{H}^c(t_{tr})$ is given by the yellow and the blue regions, considering the following system parameters: $\beta = 0.5$, $\delta = 0.2$, p = 2 and c = 5, with $U(t_{tr}) = 3$. The critical boundary of $\mathcal{H}^c(t_{tr})$ represents the critical pairs of η_β and η_p .

As it can be seen, for every inhibition effect pair $(\eta_{\beta}, \eta_p) \notin \mathcal{H}^c(t_{tr})$ (*i.e.* a point inside the red region in Figure 4) the antiviral treatment is ineffective. On the other hand, as it is shown in Theorem 4.1, for every pair (η_{β}, η_p) such that $\eta_{\beta} > \eta_{\beta}^c(t_{tr})$ or $\eta_p > \eta_p^c(t_{tr})$ (the yellow region in Figure 4) the antiviral treatment is effective. Finally, for pairs in the region inside $\mathcal{H}^c(t_{tr})$ with $\eta_{\beta} < \eta_{\beta}^c(t_{tr})$ and $\eta_p < \eta_p^c(t_{tr})$ (which does not fit conditions in Theorem 4.1 and it is represented by the blue region in Figure 4) the antiviral treatment is still effective.

5. Within-Host Modeling of COVID-19

In this section, the parameters of model (2.1) are estimated using viral load data of 9 RT-PCR COVID-19 positive patients, labeled as A,B,C,D,E,F,G,H and I, reported by Woelfel et. al. [22]. We follow a similar procedure as in Vargas et. al. [12]. Since the viral load is measured in Log10 scales, the model fitting was fulfilled by minimizing the root mean squared of logarithmic error (RMSLE), denoted as:

$$RMSLE = \sqrt{\frac{1}{n} \sum_{i=1}^{n} (\log(y_i) - \log(\bar{y}_i))^2},$$
(5.1)

where *n* is the number of measurements, y_i the model predictive output, and \bar{y}_i the experimental measurement. Since the minimization of 5.1 implies a nonlinear optimization problem, with highly dependence on initial conditions, the Differential Evolution (DE) algorithm [43, 24] is employed as a global optimization algorithm, which has shown to be robust to initial guesses of parameters [44].

Even though it is still debatable which compartments SARS-CoV-2 can infect, there is a common agreement that the viral shedding take places mainly in the respiratory epithelial cells (due to the high expression of ACE2) with direct viral toxicity of the infected cells [45]. Therefore, following previous works of mathematical modelling for influenza infection in humans, the value of U_0 is taken as about 4×10^8 cells for all patients [16]. Furthermore, I_0 is assumed to be 0 and V_0 was estimated (using a regression model, since the viral at the day of infection was not provided) [12] to be about 0.31 Copies/mL. Moreover, in order to avoid identifiability problems related with the fact that only viral titters are used to fit the model, the viral clearance parameter (c) was set in 2.4 1/day, which is in accordance with previous estimates for influenza and HIV [46, 16]. The parameters and initial condition (at the time of infection t = 0) of each patient are collected in Table 1. Since the viral load was measured after the onset of the symptoms, an incubation period of 7 days post infection (dpo) was assumed for the time of infection, according to [12].

| Patient | β | δ | p | c |
|---------|-----------------------|------|-------|-----|
| Α | 1.35×10^{-7} | 0.61 | 0.2 | 2.4 |
| В | 1.26×10^{-7} | 0.81 | 0.2 | 2.4 |
| С | 5.24×10^{-7} | 0.51 | 0.2 | 2.4 |
| D | 7.92×10^{-10} | 1.21 | 361.6 | 2.4 |
| E | $1.51 	imes 10^{-7}$ | 2.01 | 0.2 | 2.4 |
| F | 5.74×10^{-10} | 0.81 | 382 | 2.4 |
| G | 1.23×10^{-7} | 0.91 | 0.2 | 2.4 |
| Н | 2.62×10^{-9} | 1.61 | 278.2 | 2.4 |
| Ι | 3.08×10^{-10} | 2.01 | 299 | 2.4 |

Table 1: Target cell-limited model parameter values for COVID-19 patients [12]

The time evolution of U, I and V is shown in Figure 5, for each patient. As it can be seen, the plot confirms the results in Theorem 3.2 concerning the minimum and maximum times of V, the maximum time of I and the time when U reaches U_c (*i.e.*, when $\mathcal{R}(t)$ reaches 1). Figure 5 also confirms the approximation made in Remark 4, by showing that virus and infected cell peaks occur approximately at the same time at which U reaches U_c . All these time values, together with the values of U_c (the critical target cell value), U_{∞} (the final value of U, when the virus is died out), \mathcal{R}_0 and the virus maximum are shown in Table 2, for the nine simulated patients.



Figure 5: U,I,V time evolution for the untreated case. As stated in Theorem 3.2, $\check{t}_V < \hat{t}_I < t_c < \hat{t}_V$, where \check{t}_V and \hat{t}_V are the times at which V(t) reaches a local minimum and a local maximum, respectively, \hat{t}_I is the time at which I(t) reaches a local maximum, and t_c is the time at which U(t) reaches \mathcal{U}_c . Furthermore, as stated in Remark 4, $\check{t}_V \approx 0$ and $\hat{t}_I \approx t_c \approx \hat{t}_V$. $V_{undet} = 50$ (Copies/mL) stands for the undetectable level of the virus load.

| Patient | \mathcal{U}_c (×10 ⁸) | U_{∞} | \mathcal{R}_0 | \check{t}_V | \hat{t}_I | t_c | \hat{t}_V | V_{max} |
|---------|-------------------------------------|----------------------|-----------------|---------------|-------------|-------|-------------|-----------------------|
| А | 0.54 | 0.26×10^{6} | 7.35 | 0.22 | 10.53 | 10.61 | 10.95 | 1.50×10^{7} |
| В | 0.77 | 0.23×10^{7} | 5.17 | 0.24 | 11.81 | 11.90 | 12.20 | 1.18×10^{7} |
| С | 0.12 | 0.00 | 34.22 | 0.06 | 3.94 | 3.99 | 4.42 | 2.10×10^{7} |
| D | 0.10 | 0.00 | 39.47 | 0.02 | 3.00 | 3.05 | 3.39 | 2.90×10^{10} |
| E | 1.60 | 4.27×10^{7} | 2.50 | 0.23 | 14.31 | 14.47 | 14.69 | 0.42×10^7 |
| F | 0.09 | 0.00 | 45.12 | 0.03 | 3.48 | 3.53 | 3.93 | 3.55×10^{10} |
| G | 0.90 | 0.47×10^7 | 4.50 | 0.25 | 12.44 | 12.53 | 12.83 | 1.04×10^{7} |
| Н | 0.05 | 0.00 | 75.57 | 0.00 | 1.73 | 1.77 | 2.11 | 2.02×10^{10} |
| Ι | 0.52 | 0.19×10^6 | 7.64 | 0.07 | 6.77 | 6.86 | 7.09 | 1.50×10^{10} |

Table 2: Parameter Characterization of COVID-19 patients. The times are given in days post infection (dpi).

Remark 7. In comparison with other coronavirus diseases, such as MERS and SARS, where the virus load peak takes place after the onset of symptoms (7 - 10 days post infection) [47], for SARS-CoV-2 infection it is not clear the temporal interval where the viral load reaches a peak. A recent study linking epidemiological and viral load data, suggests that the viral load peak occurs during the day of symptom onset [47]. However, observation of viral load in infected macaques [48, 49] denotes that the viral peak from nose and throat swabs happens during the 1-3 days post infection. Therefore, since the target cell model fitting was conducted using SARS-CoV-2 viral load measured after the onset of the symptoms [22], the estimated time-to-peak (\hat{t}_V) in Table 2 is subject to practical identifiability problems, which as was indicated in Theorem 4.1 and will be shown in Section 6, is a main parameter to evaluate antiviral effectiveness. Due to this reason, an uncertainty analysis computing the likelihood-based confidence intervals [50] for each parameter was done. In Figure 6 such analysis is shown for the 95% confidence interval of parameter p, where it can be seen the high degree of uncertainty in the estimated \hat{t}_V for patients A, C, F and G (approximately 5 days).



Figure 6: Uncertainty analysis on viral load evolution for *p*-parameter 95% confidence interval. Note the uncertainty in viral load peak. Empty dots are data of COVID-19 patients.

6. Simulation Results

To evaluate the results concerning the antiviral treatment effectiveness, several simulations involving the nine patients introduced in Section 5 were performed. First, the virus spreading interval - the time between the estimated day of infection (7 *dpo*) and the time-to-peak of viral load (\hat{t}_V) - will be considered in Section 6.1, to assess the results of Theorem 4.1. Due to the reported variability on the estimated time-to-peak (Figure 6), we decided to initialize the treatments taking into account the relative time with respect to the estimated \hat{t}_V , instead of a fixed time for all the population. Furthermore, the (maximal) early treatment time (t^e) of each patient was computed numerically, being of the order of 0.77 [0.74, 0.79] \hat{t}_V .

Then, in Section 6.2 the case when the antiviral therapy is started before and after the untreated timeto-peak \hat{t}_V is simulated, in order to analyze the sub-potent/potent drug efficacy as treatment time t_{tr} is delayed. Finally, in Section 6.3 the synergistic effects of antiviral therapies blocking the viral replication p and the host cell infection β are studied, taking into account the combined drug effect analysis made in Section 4.2.

To numerically assess the viral kinetics evolution the following infected-related metrics are employed: i) the difference of viral loads with and without treatment at time-to-peak, $\Delta V = V(\hat{t}_V) - V(\hat{t}_{V,tr})$, which is a measure of the viral reduction at time-to-peak respect to the untreated case [13]; ii) the duration of infection, *DI*, defined as the time spent by the viral titer curve over a detection limit of 100 copies/ml, which is a measure of the viral shedding interval, and iii) the time-to-peak \hat{t}_V , which is an indicator of the viral replication rate. For the sake of simplicity, unless otherwise stated, the approximation of system (2.1) presented in Remark 4 is used for simulations.

6.1. Treatment initiated at different times, during viral spreading interval $(t_{tr} \in (\check{t}_V, \hat{t}_V))$

Scenario 1: Treatment is initiated at viral load detection level ($t_{tr} = t_{DL}$)

Figure 7 shows the simulated virus load evolution corresponding to each of the nine patients, when the antiviral therapy is started at the first positive PCR test day $(t_{tr} = t_{DL})$, being t_{DL} the time at which the virus reaches the value DL = 100 copies/mL), which is about $0.3\hat{t}_V \approx 0.40t^e$. Consequently, all the patients fall in the case $\check{t}_V < t_{tr} < t^e < \hat{t}_V$ which means that we are under the hypothesis of Theorem 4.1 and, furthermore, the treatment time belongs to the early treatment time interval. To properly asses the antiviral replication inhibition effect, increasing values of η_p were used. First we started with small values of η_p , fulfilling the condition $\eta_p < \eta_p^c(t_{tr})$ (item iii in Theorem 4.1, ineffective treatment). Then η_p was set to a value equal to $\eta_p^c(t_{tr})$, to reinforce the counter-intuitive fact that larger inhibition effects fulfilling $\eta_p < \eta_p^c(t_{tr})$ produce larger virus peak times (item iv in Theorem 4.1). Finally, η_p was increased to two values larger than $\eta_p^c(t_{tr})$ (items i and ii in Theorem 4.1), to show that higher inhibition effects produce faster eradication of the virus V.

As expected, effective treatments produce an instantaneous decline of the viral load, with a monotonically decreasing viral shedding interval as the antiviral efficacy is incremented. On the other hand, ineffective treatments cause a delay in time to peak, significantly increasing the duration of viral shedding as η_p is augmented from 0 to η_p^c . Even when the viral load peak is a monotonically decreasing function of η_p (by following similar steps than the ones in Lemma 1 it can be shown that $\partial V(\hat{t}_{V,tr})/\partial \mathcal{R} = (\delta/\beta)(1-\frac{1}{\mathcal{R}})$, for $\mathcal{R} := \mathcal{R}(t_{tr}) \geq 1$, with $\mathcal{R}(t_{tr}) = (1 - \eta_p)p\beta/(c\delta)$), the patient will be PCR-positive for longer periods of time. This means that isolation and precautions measures with treated patients should be carefully considered, depending on the antiviral effectiveness.

Figure 8 shows a box-plot of the infected-related metrics for the antiviral effectiveness assessment. For an effective antiviral therapy $(\eta_p > \eta_p^c(t_{tr}))$, the difference of viral loads at time-to-peak (ΔV) is above the 2 logs threshold [13] and the duration of infection (DI) is below the 30 days limit (according [51] the viral shedding interval for untreated COVID-19 patients is in order of 30 days) which is in accordance with an effective viral clearance strategy. On the other hand, for ineffective antiviral therapy ($\eta_p < \eta_p^c(t_{tr})$), even tough ΔV is monotonically increasing with η_p , the duration of infection is increased to a sub-potent drug efficacy. This means that the delay of the virus peak associated to ineffective treatments is significant in terms of the infected-related metrics.

Scenario 2: treatment initiated in the course of viral spreading

Figures 9 and 10 show the virus load evolution when the antiviral therapy is started in the course of viral spreading, at $t_{tr} \approx 0.7t^e$ and $t_{tr} \approx t^e$, respectively. The viral load over the time has the same qualitative



Figure 7: Free virus behavior when treatment is started at viral load detection level ($t_{tr} = t_{DL}$). Values of η_p smaller (η_p^1, η_p^2), approximately equal (η_p^3, η_p^4) and greater (η_p^5, η_p^6) than η_p^c are simulated to demonstrate the results in Theorem 4.1. The black line denotes the untreated case ($\eta_p = 0$).



Figure 8: Infection-related metrics as function of η_p ($t_{tr} = t_{DL}$), for antiviral effectiveness assessment.

behavior than in the previous case. However, the duration of the infection is longer as the inhibition effect approaches $\eta_p^c(t_{tr})$ from below and from above (*i.e.*: η_p^3 and η_p^4 cases, violet and green lines in Figures

9 and 10). Indeed, for values of drug effectiveness in the vicinity of $\eta_p^c(t_{tr})$, the viral duration interval is augmented - even for effective therapies - since V has already reached a relatively high value at the treatment time. This behavior is confirmed in box-plots 11 and 12, where a sudden increase of the duration of infection happens when the antiviral efficacy is near the critical value. However, as the treatment time is delayed this behavior is mitigated (see box-plot 12) due to the natural increment of $V(t_{tr})$ (recall that $\dot{V}(t) \approx (\mathcal{R}(t_{tr}) - 1)\delta V(t)$, for $t > t_{tr}$, so larger values of $V(t_{tr})$ produce larger values of $|\dot{V}(t)|$). It is important to remark that, even when an increased duration of the viral shedding is reported for the effective treatment case in the boundary of critical drug effectiveness ($\eta_p \approx \eta_p^c$), the viral load peak occurs previous to \hat{t}_V , in accordance with items i and ii of Theorem 4.1.



Figure 9: Viral load time evolution with treatment initial time given by $t_{tr} = 0.7t^e$. Values of η_p smaller, approximately equal and greater than η_p^c are simulated to demonstrate the results in Theorem 4.1.The black line denotes the untreated case ($\eta_p = 0$).

6.2. Treatment initiated at different times, with the same effectiveness

In order to analyze the viral kinetics when the antiviral therapy is initiated at any time in the whole infection period (*i.e.*, before and after \hat{t}_V), we studied the temporal dependence of infection-related metrics corresponding to fixed sup-potent/potent drug effectiveness. Only two representative patients (labeled as B and E) were considered, based on the uncertainty analysis made in Section 5. The treatment initial times were: $t_{tr1} = 4$, $t_{tr2} = 6$, $t_{tr3} = 9$, $t_{tr4} = 17$, $t_{tr5} = 20$ and $t_{tr6} = 25$ dpi. Figures 13 and 14 (left) show that if an ineffective treatment is initiated ($\eta_{pB} = 0.73$ for patient B and $\eta_{pE} = 0.54$ for patient E, with $\eta_{pB}^c(t_{tr}) \approx 0.81$ and $\eta_{pE}^c(t_{tr}) \approx 0.6$ for $t_{tr} < t^e$), the time-to-peak ($\hat{t}_{V,tr}$) and the duration of infection (*DI*) decrease as the treatment time is delayed. This can be explained by the fact that, for the same effectiveness, $\hat{t}_{V,tr}$ is reduced as $V(t_{tr})$ is augmented. Equations (8.4) and (8.5) in Lemma 1 show that for a fixed $\mathcal{R} \ge 1$, $k_1(\mathcal{R}) \ge 0$ and $k_2(\mathcal{R}) \le 0$ are increasing functions of $V(t_{tr})$ (*i.e.*: $k_1(\mathcal{R}) = 0$ and $k_2(\mathcal{R}) = -1/(\delta(\mathcal{R}-1))$ for $V(t_{tr}) \to 0$ while $k_1(\mathcal{R}) = 1/((1-\mathcal{R})^2 + \mathcal{R})$ and $k_2(\mathcal{R}) = -1/(\delta\mathcal{R})$ for $V(t_{tr}) \to \delta/\beta$, being $\delta/\beta < V(\hat{t}_V)$). Therefore, since $\hat{t}_{V,tr} = k_2 \ln(k_1) + t_{tr}$ (according to equation (8.3)), it can be inferred that $\hat{t}_{V,tr}$ is monotonically decreasing with $V(t_{tr})$. Moreover, comparing the viral load at the time-to-peak, it can be deduced that $V(\hat{t}_{V,tr2}) > V(\hat{t}_{V,tr1})$ for an ineffective therapy started at two treatment times $t_{tr2} > t_{tr1}$ during the beginning of the infection (assuming that $U(t_{tr1}) \approx U(t_{tr2})$).



Figure 10: Viral load time evolution with treatment initial time given by $t_{tr} = t^e$. Values of η_p smaller, approximately equal and greater than η_p^c are simulated to demonstrate the results in Theorem 4.1. The black line denotes the untreated case ($\eta_p = 0$).



Figure 11: Infection-related metrics as function of η_p ($t_{tr} = 0.7t^e$), for antiviral effectiveness assessment.

By following similar steps as in Lemma 1, the viral load at the time-to-peak can be written as: $V(\hat{t}_{V,tr}) = V(t_{tr}) + (p/c)U(t_{tr}) - (\delta/\beta)(\ln(\mathcal{R}_{tr}) + 1)$ and, therefore, $V(\hat{t}_{V,tr2}) - V(\hat{t}_{V,tr1}) = V(t_{tr}) + (p/c)U(t_{tr}) - (\delta/\beta)(\ln(\mathcal{R}_{tr}) + 1)$



Figure 12: Infection-related metrics as function of η_p ($t_{tr} = t^e$), for antiviral effectiveness assessment.

 $V(t_{tr2}) - V(t_{tr1}) > 0$. However, from Figures 13 and 14 (right) it can be seen that $V(\hat{t}_{V,tr})$ is of the order of 10⁶ and 10⁵ copies/ml for patients B and E, respectively, independently of the treatment initiation time. This can be explained by the fact that the difference of viral load at $t_{V,tr}$, for therapies started at different times, depends mainly on the deviation between the viral loads at treatment times, which normally are several order of magnitude below $V(\hat{t}_{V,tr})$. For example, for patient B, $V(\hat{t}_{V,tr1}) = 3.29 \times 10^5$, $V(\hat{t}_{V,tr2}) = 3.30 \times 10^5$ and $V(\hat{t}_{V,tr3}) = 4.35 \times 10^5$ Copies/ml while $V(t_{tr1}) = 10^2$, $V(t_{tr2}) = 2.5 \times 10^3$ and $V(t_{tr3}) = 1.74 \times 10^5$ Copies/ml. Consequently, the increment on the viral peak is not significant as the treatment is delayed, although the duration of infection is considerably reduced (*i.e.*: from 96 to 55 days for patient B and 95 to 65 days for patient E). Note that the target cell-model assumes that the viral clearance in the convalescent phase is proportional to the virus load concentration at time-to-peak, which is in the same order of magnitude for the three cases. As a result, and taking into account that the viral peak is reached early as the treatment is delayed, a quickly viral deletion is observed for the postponed case. As a consequence, if a fixed sub-potent drug is employed, delaying the treatment initiation time could reduce viral shedding interval, without significantly increasing the viral load at time-to-peak. It is important to remark that if η_p is reduced even more ($\eta_p \ll \eta^c$), the viral at time-to-peak follows the same behavior, although, the viral shedding interval is not-considerably decreased, since $\hat{t}_{V,tr} \approx \hat{t}_V$ as $\eta \to 0$ $(t_{tr} \in (\check{t}_V, \hat{t}_V))$. Hence, although a non-significant improvement on the duration of infection is achieved if the treatment is delayed, the viral outcomes continues to be acceptable.

On the other hand, if the ineffective therapy is initiated after the viral load peak, the duration of infection is slightly reduced with respect to the previous case, since $R(t_{tr}) < 1$ at this time and, therefore, $\dot{V} = (\mathcal{R}(t_{tr}) - 1)\delta V(t)$ is a decreasing function of $V(t_{tr})$. In contrast to this, Figures 13 and 14 (right) show that if an effective antiviral therapy is applied ($\eta_{pB} = 0.9$ for patient B and $\eta_{pE} = 0.8$ for patient E) the duration of the infection is still decreased, since $\mathcal{R}_1(t_{tr4}) < \mathcal{R}_2(t_{tr4})$ for both, patient B and patient E, being \mathcal{R}_i the within-host basic reproduction number under a treatment with inhibition effect η_p^i , being $\eta_p^1 = 0.9$ and $\eta_p^2 = 0.73$ for patient B and $\eta_p^1 = 0.8$ and $\eta_p^2 = 0.54$ for patient E.

6.3. Treatment with antiviral inhibiting both viral infection (η_{β}) and viral replication rate (η_{p})

Finally, the virus behavior was considered when a combined antiviral therapy inhibiting both, the viral infection rate (β) and the viral replication rate (p), was applied. Since the critical drug efficacy for acute models is defined during the viral spreading interval (Section 4), the treatment was initiated at $t_{tr} = 0.7t^e$, which is a value fulfilling $t_{tr} \in (\check{t}_V, \hat{t}_V)$.



Figure 13: Virus time evolution for different treatment times, $t_{tr} = 4, 6, 8, 17, 20, 25$ (dpi). Two fixed values of η_p were used, smaller and bigger than $\eta_p^c(t_{tr})$: $\eta_p = 0.73$ (left) and $\eta_p = 0.9$ (right), respectively. $\eta_p^c(t_{tr}) \approx 0.81$ for $t_{tr} < t^e$. Patient B.

For the sake of clarity, only Patient A is considered and the 3 previous infection-related metrics are assessed as functions of the antiviral inhibition effects η_p and η_β . Figure 15 shows that the antiviral is effective for every inhibition effect pair (η_β, η_p) fulfilling $(\eta_\beta, \eta_p) \in \mathcal{H}^c(t_{tr})$ (*i.e.*: yellow region of ΔV), in accordance with the results in Section 4.2. Moreover, as for the single inhibition cases, the duration of infection and the time-to-peak increase as the combined drug efficacy pair (η_β, η_p) tends to the boundary of $\mathcal{H}^c(t_{tr})$. The difference of viral load at time-to-peak ΔV remains constant for every $(\eta_\beta, \eta_p) \in \mathcal{H}^c(t_{tr})$ since $V(\hat{t}_{V,tr}) = t_{tr}$ for effective treatments. In conclusion, the synergistic effect of drug effectiveness in combined therapies produces a reduction on the critical effectiveness with respect to single-therapies cases, with the same dynamical behavior over the boundary of $\mathcal{H}^c(t_{tr})$.

7. Discussion

While several vaccines have been developed to prevent COVID-19 disease, it is imperative to evaluate potential therapies against SARS-CoV-2 infection. Among them, antiviral treatments are promissory strategies to increment the viral clearance "within-host", decreasing disease severity. In this sense, the drug effectiveness concept is crucial to evaluate the drug effect threshold above which the viral load starts declining [52]. Although this critical value has been described for chronic infections (e.g. HIV [52, 53], HCV [35]) it has not been studied yet for COVID-19. The critical drug efficacy can be understood in terms of the antiviral potency to decline viral spreading, in spite of guiding the system to an uninfected equilibrium, as it was introduced in Definition 4, Section 4.2. In addition, the critical inhibition effect of an antiviral depends on the treatment initiation time, and it has shown to be a monotonically decreasing function during the viral spreading interval (roughly speaking, during the time interval before the untreated virus peak).

Regarding the virus behavior for effective therapies ($\eta > \eta^c$), the viral load at time-to-peak is practically equal to $V(t_{tr})$ (*i.e.*, a treatment is considered effective if the virus starts to decrease at the very moment the treatment is initiated, by modifying either η_p , η_β , or both), so ΔV is larger for earlier treatments, being greater than the 2 log threshold for effective antiviral therapies started at $t_{tr} < t^e$ ($t^e \approx 0.75 \hat{t}_V$).



Figure 14: Virus time evolution for different treatment times, $t_{tr} = 4, 6, 8, 17, 20, 25$ (dpi). Two fixed values of η_p were used, smaller and bigger than $\eta_p^c(t_{tr})$: $\eta_p = 0.54$ (left) and $\eta_p = 0.8$ (right), respective. $\eta_p^c(t_{tr}) \approx 0.6$ for $t_{tr} < t^e$. Patient E.



Figure 15: Infection-related metrics for antiviral effectiveness assessment as function of η_p and η_β ($t_{tr} = 0.7t^e$). Patient A

Nevertheless, for η approaching η^c (from above), the viral shedding interval is enlarged as the treatment is initiated during the infection growth. Therefore, if the therapeutic objective is to reduce both, the viral shedding interval and the viral peak, the efficacy level would need to overpass the critical value in a given

quantity. From Figure 3 it can be seen that $\eta^{c}(t_{tr}) > 0.7$ for most of patients.

Simulations results suggest that for ineffective therapies, the virus would take longer to be cleared rather than a monotonic decline, as in the previous case - reaching a peak and finally decreasing to zero. In spite of the fact that the viral load at time-to-peak decreases monotonically with η (ΔV increases as the inhibition effect jumps from 0 to $\eta > 0$), the time-to-peak increases as η approaches η^c (from below), which results in a longer duration of infection, potentially requiring additional isolation measures for the treated patient.

Although an effective reduction of the viral load peak and the duration of infection could be achieved with early treatments (treatments started before the untreated peak), minor effects are attained with late ones. Particularly, Figures 13 and 14 corroborate a slight reduction on the viral shedding interval if a subpotent drug therapy is employed after the time-to-peak. Consequently, taking into account that the viral load in COVID-19 patients presumably reaches the peak prior to the symptom onset, no further clinical improvements may be obtained if the therapy is started in this symptomatic phase (*i.e.*: notice that SARS-CoV-2 pathophysiology is characterized by a direct cytotoxic effect, endothelial cell damage, dysregulation of immune response, among others [45]). Furthermore, considering the analysis presented in Theorem 4.1 that is valid during viral spreading interval, we can argue that the non-significant antiviral effect reported recently in [54] might be related to an early time-to-peak of COVID-19 patients.

The effectiveness of combined treatments affecting both, η_p and η_β , was also studied and an interdependent critical drug efficacy level was computed. Mathematically, the critical combination of values of η_p and η_β is placed on the boundary of the effective set $\mathcal{H}^c(t_{tr})$, which is a set in the η_p , η_β space. In comparison with single treatment cases (represented by the horizontal and vertical dash-dot lines in Figure 15), a reduced critical antiviral efficacy was reported for the combined case, denoting a reduction on the necessary drug effectiveness to reduce viral spreading. Moreover, the viral characteristic behavior in the vicinity of the critical drug efficacy (*i.e.*: increase of time-to-peak and duration of infection) was preserved for the combined case, as the pair (η_β , η_p) belongs to the critical boundary of $\mathcal{H}^c(t_{tr})$, which implies that the antiviral effectiveness characterization made in Theorem 4.1 for single treatments could be extended to combined therapies.

In sum, this work formalizes the existence of a critical drug efficacy for acute infection models, which could have implications in the extended viral shedding observed "in-silico" by [55] (for SARS-CoV-2 infections) and by [56] (for influenza) when the antiviral therapy is initiated early but with a sub-potent drug efficacy. Moreover, it was shown the importance of initialization the antiviral therapy early (before viral load peak) in order to achieve a significant reduction of ΔV and DI [13, 57]. Although a time dependence was noticed for the critical drug efficacy ($\eta_p^c(t), \eta_{\beta}^c(t)$), since it is a decreasing function of t (Figure 3), its behavior does not compromise the antiviral success if an effective therapy is started later.

The main clinical implications for acute infections, and, particularly, for the SARS-CoV-2 infection are: a) importance of viral load monitoring on probably infected COVID-19 patients (prophylactic use of antiviral therapy, previous to onset of symptoms, although adverse effects have been reported for potential antiviral drugs [36], which could limited their prophylactic usage in risk patients), b) isolation of treated patient, c) possible explanation of the increase of duration of infection showed in immune compromised COVID-19 patients.

8. Appendix 1. Technical lemmas

Lemma 1. Consider (4.1), constrained by the positive set \mathbb{X} , at the beginning of the infection t = 0, with $U(0) > \mathcal{U}_c$, $I(0) \ge 0$ and V(0) > 0. Consider that at some time $t_{tr} > 0$, $\eta_p(t)$ jumps from 0 to $\eta_p > \eta_p^c$, being η_p^c the critical value defined in (4.4). Then, there exists $t^e(\eta_p, t_{tr})$ such that if $t_{tr} \in (\check{t}_V, t^e]$, the virus peak time $\hat{t}_{V,tr}$ (considering the treatment effect) is a decreasing function of $\mathcal{R}(t_{tr})$.

Proof: Consider the approximation 3.5, in Remark 4. Since $\eta_p(t)$ jumps from 0 to $\eta_p < \eta_p^c$, at t_{tr} , then $\mathcal{R}(t)$ jumps from $\mathcal{R}(t_{tr}^-)$ to $\mathcal{R}(t_{tr})$, with $\mathcal{R}(t_{tr}) \in (\mathcal{R}(t_{tr}^-), 1)$ and $\mathcal{R}(t_{tr}^-) > 1$. Then it is possible to approximate the explicit solutions for U(t) and V(t) (by approximating the $\ln(z)$ function in the time interval before the virus peak by $(z-1)(\frac{w_1}{z}+w_2)$, being w_1 and w_2 arbitrary constants, fulfilling $w_1 + w_2 = 1$ [58]. So, U(t), for $t > t_{tr}$, can be written as

$$U(t) = \frac{(B + \sqrt{B^2 - 4AC})k_{t_{t_r}}^N e^{-(\beta/U(t_{t_r}))\sqrt{B^2 - 4AC}(t - t_{t_r})} - k_{t_{t_r}}^D (B - \sqrt{B^2 - 4AC})}{2Ak_{t_{t_r}}^D - 2Ak_{t_{t_r}}^N e^{-(\beta/U(t_{t_r}))\sqrt{B^2 - 4AC}(t - t_{t_r})}},$$
(8.1)

where

$$\begin{split} k_{t_{tr}}^{N} &= 2AU(t_{tr}) + B - \sqrt{B^{2} - 4AC}, \\ k_{t_{tr}}^{D} &= 2AU(t_{tr}) + B + \sqrt{B^{2} - 4AC}, \\ A &= -\frac{p(1 - \eta_{p})}{c}U(t_{tr}) + \frac{\delta}{\beta}w_{2}, \\ B &= U(t_{tr})(\frac{\delta}{\beta}w_{1} - \frac{\delta}{\beta}w_{2} + V(t_{tr}) + \frac{p(1 - \eta_{p})}{c}U(tr)), \\ C &= -\frac{\delta}{\beta}U(t_{tr})^{2}w_{1}. \end{split}$$

A reasonable approximation, however, can be obtained by selecting $w_1 = 0$ and $w_2 = 1$ (also $w_1 = 0.2$ and $w_1 = 0.8$ gives a good result, but clearly the former selection significantly simplifies the expressions). In such a case, A, B, C, $k_{t_{tr}}^N$ and $k_{t_{tr}}^D$ read:

$$\begin{aligned} A &\approx -U(t_{tr})\frac{p(1-\eta_p)}{c} + \frac{\delta}{\beta} = (1-\mathcal{R}(t_{tr}))\frac{\delta}{\beta} < 0, \\ B &\approx U(t_{tr})(-\frac{\delta}{\beta} + V(t_{tr}) + U(t_{tr})\frac{p(1-\eta_p)}{c}) = -U(t_{tr})A + U(t_{tr})V(t_{tr}) > 0, \\ C &\approx 0, \\ k_{t_{tr}}^N &\approx 2AU(t_{tr}), \\ k_{t_{tr}}^D &\approx 2AU(t_{tr}) + 2B = 2U(t_{tr})V(t_{tr}), \end{aligned}$$

being $\mathcal{R}(t_{tr}) = U(t_{tr}) \frac{\beta p(1-\eta_p)}{c\delta}$. This way, U(t) can be simplified as

$$U(t) = \frac{2B2AU(t_{tr})e^{-(\beta/U(t_{tr}))B(t-t_{tr})}}{2A2U(t_{tr})V(t_{tr}) - 2A2AU(t_{tr})e^{-(\beta/U(t_{tr}))B(t-t_{tr})}},$$

$$= \frac{(U(t_{tr})V(t_{tr}) - U(t_{tr})A)e^{-(\beta/U(t_{tr}))B(t-t_{tr})}}{V(t_{tr}) - Ae^{-(\beta/U(t_{tr}))B(t-t_{tr})}}$$
(8.2)

The time at which U(t) reaches \mathcal{U}_c^{tr} - *i.e.*, the time at which $\mathcal{R}(t)$ reaches 1 and V(t) reaches its peak, denoted as $\hat{t}_{V,tr}$ (with $\hat{t}_{V,tr} \ge t_{tr}$) - can be explicitly computed as

$$\hat{t}_{V,tr} = k_2 \ln(k_1) + t_{tr},$$
(8.3)

where

$$k_1 = \frac{V(t_{tr})\mathcal{U}_c^{tr}}{U(t_{tr})V(t_{tr}) - AU(t_{tr}) + A\mathcal{U}_c^{tr}}$$

$$k_2 = \frac{1}{\beta(A - V(t_{tr}))},$$

being $\mathcal{U}_c^{tr} = \frac{c\delta}{\beta p(1-\eta_p)}$ the critical value for U corresponding to the treatment parameter $p(1-\eta_p)$. Now, recalling that $\mathcal{R}(t_{tr}) = \frac{U(t_{tr})}{\mathcal{U}_c^{tr}}$, and denoting $U(t_{tr})$, $V(t_{tr})$ and $\mathcal{R}(t_{tr})$ as U, V and \mathcal{R} , respectively, for the sake of simplicity, k_1, k_2 can be rewritten as:

$$k_1(\mathcal{R}) = \frac{V}{\frac{\delta}{\beta}(1-\mathcal{R})^2 + \mathcal{R}V} > 0, \quad \forall \mathcal{R} > 1$$
(8.4)

$$k_2(\mathcal{R}) = \frac{1}{\delta(1-\mathcal{R}) - \beta V} < 0, \quad \forall \mathcal{R} > 1$$
(8.5)

This way, $\hat{t}_{V,tr} = \hat{t}_{V,tr}(\mathcal{R}) = k_2(\mathcal{R}) \ln(k_1(\mathcal{R})) + t_{tr}$ represents the time of the virus peak in terms of \mathcal{R} . Note that $\hat{t}_{V,tr}(\mathcal{R})$ is defined only for $\mathcal{R} \ge 1$; indeed, $\hat{t}_{V,tr}(1) = t_{tr}$ since $k_1(1) = 1$, while $\hat{t}_{V,tr}(\mathcal{R}) > t_{tr}$ for $\mathcal{R} > 1$.

The idea now is to consider the derivative of $\hat{t}_{V,tr}$ with respect to \mathcal{R} , to show that it is negative for treatment times t_{tr} small enough. This derivative reads:

$$\frac{\partial \hat{t}_{V,tr}}{\partial \mathcal{R}} = \frac{\partial k_2}{\partial \mathcal{R}} \ln(k_1) + k_2 \frac{1}{k_1} \frac{\partial k_1}{\partial \mathcal{R}}$$

where

$$\frac{\partial k_1}{\partial \mathcal{R}} = -\frac{V(\frac{2\delta}{\beta}(\mathcal{R}-1)+V)}{(\frac{\delta}{\beta}(1-\mathcal{R})^2 + \mathcal{R}V)^2}$$
(8.6)

$$\frac{\partial k_2}{\partial \mathcal{R}} = \frac{\delta}{(\delta(1-\mathcal{R}) - \beta V)^2}.$$
(8.7)

Since $\frac{\partial k_2}{\partial \mathcal{R}} > 0$ for $\mathcal{R} > 1$, condition $\frac{\partial \hat{t}_{V,tr}}{\partial \mathcal{R}} < 0$ can be written as

$$\ln(k_1) < -\frac{k_2}{k_1} \frac{\partial k_1}{\partial \mathcal{R}} (\frac{\partial k_2}{\partial \mathcal{R}})^{-1}.$$
(8.8)

Furthermore, given that $\ln(\cdot)$ is an increasing function on $(0,\infty]$, it follows that

$$k_1 < e^{-\frac{k_2}{k_1}\frac{\partial k_1}{\partial \mathcal{R}}(\frac{\partial k_2}{\partial \mathcal{R}})^{-1}}.$$
(8.9)

Then, by replacing (8.4), (8.5), (8.6) and (8.7) in inequality (8.9), we have:

$$\frac{\beta}{\delta}V < [(1-\mathcal{R})^2 + \mathcal{R}\frac{\beta}{\delta}V]e^{\frac{-2(1-\mathcal{R})^2 + 2\frac{\beta}{\delta}V(1-\mathcal{R}) - \frac{\beta}{\delta}^2V^2}{(1-\mathcal{R})^2 + \frac{\beta}{\delta}\mathcal{R}V}}}$$

Now, for $\mathcal{R} > 1$ the exponent is negative, so function

$$f(\frac{\beta}{\delta}V) := [(1-\mathcal{R})^2 + \mathcal{R}\frac{\beta}{\delta}V]e^{\frac{-2(1-\mathcal{R})^2 + 2\frac{\beta}{\delta}V(1-\mathcal{R}) - \frac{\beta}{\delta}^2V^2}{(1-\mathcal{R})^2 + \frac{\beta}{\delta}\mathcal{R}V}}$$

starts at the positive value $(1 - \mathcal{R})^2 e^{-2}$, for V = 0, then increases to a maximum and finally decreases asymptotically to zero, for $V \to \infty$. So, there exists some interval of V, maybe small, such that V < f(V). Figure 16 shows a plot of f(V) for different values of $\mathcal{R} > 1$.

Finally, since we are considering the treatment time to belong to the increasing period of V(t) (*i.e.*, $t_{tr} \in (\check{t}_V, \hat{t}_V)$, with $V(\check{t}_V) \approx 0$, then small values of V(t) correspond to small values of t. So, a time interval $(\check{t}_V, t^e]$ exists such that $\hat{t}_{V,tr}$ is a decreasing function of $\mathcal{R}(t_{tr})$, and the proof is complete. Figure 17 shows the time evolution of $\mathcal{R}(t)$ when the antiviral treatment is initiated at $0.75\hat{t}_V$ and different antiviral

inhibition effects are considered, for the real data patients simulated in Sections 5 and 6. As it can be seen, larger values of η_p (or smaller values of $\mathcal{R}(t_{tr})$) corresponds always with larger values of $\hat{t}_{tr,V}$. \Box



Figure 16: Qualitative plot of function f(V) (arbitrary parameters) for different values of \mathcal{R} . As it can be seen - independently of the parameter values - if $\mathcal{R}(t_{tr}) > 1$ it there exists an interval of values of V, and a corresponding period of time such that f(V) > V.



Figure 17: Evolution of $\mathcal{R}(t)$ when an antiviral treatment is initiated at a time of approximately 0.75 \hat{t}_V , and different antiviral inhibition effects η_p are considered, smaller and greater than the critical value η_p^c . The black dashed line represents $\mathcal{R} = 1$. As it can be seen, for values of $\eta_p < \eta_p^c$, $\mathcal{R}(t)$ crosses 1 at larger times for larger values of η_p as it is stated in Lemma 1. This implies that if $\eta_p < \eta_p^c$, larger values of η_p delays the virus peak time, as it is stated in Theorem 4.1.iii. Furthermore, the figure confirms that, for real patient date, t^e is close to \hat{t}_V .

References

- Coronavirus disease 2019 (COVID-19) Situation Reports, https://www.who.int/emergencies/diseases/no Accessed: 2020-12-28.
- [2] COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, https://coronavirus.jhu.edu/map.html, Accessed: 2020-04-28.
- [3] M. S. Khan, I. Shahid, S. D. Anker, S. D. Solomon, O. Vardeny, E. D. Michos, G. C. Fonarow, J. Butler, Cardiovascular implications of COVID-19 versus influenza infection: a review, BMC medicine 18 (1) (2020) 1–13.
- [4] O. Mitjà, B. Clotet, Use of antiviral drugs to reduce COVID-19 transmission, The Lancet Global Health.
- [5] J. Gao, Z. Tian, X. Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, BioScience Trends 14. doi:10.5582/bst.2020.01047.
- [6] X. Yao, F. Ye, M. Zhang, C. Cui, B. Huang, P. Niu, X. Liu, I. Zhao, E. Dong, C.-L. Song, S. Zhan, R. Lu, H. Li, D. Liu, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americadoi:10.1093/cid/ciaa237.
- [7] A. Kalil, Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics, JAMA 323. doi:10.1001/jama.2020.4742.
- [8] P. Colson, J.-M. Rolain, J.-C. Lagier, P. Brouqui, D. Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, International Journal of Antimicrobial Agents 55 (2020) 105932. doi:10.1016/j.ijantimicag.2020.105932.
- [9] N. H. Commission, et al., Translation: Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7), Infectious Microbes & Diseases (2020) 48–54.
- [10] J. M. Sanders, M. L. Monogue, T. Z. Jodlowski, J. B. Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA.
- [11] S. Tett, D. Cutler, R. Day, K. Brown, Bioavailability of hydroxychloroquine tablets in healthy volunteers, British journal of clinical pharmacology 27 (1989) 771–9. doi:10.1111/j.1365-2125.1989.tb03439.x.
- [12] E. A. Hernandez-Vargas, J. X. Velasco-Hernandez, In-host Modelling of COVID-19 Kinetics in Humans, medRxiv.
- [13] A. Goncalves, J. Bertrand, R. Ke, et al., Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load. medrxiv, Preprint 10 (2020.04) (2020) 04–20047886.
- [14] G. Giordano, F. Blanchini, R. Bruno, P. Colaneri, A. Di Filippo, A. Di Matteo, M. Colaneri, et al., A SIDARTHE model of COVID-19 Epidemic in Italy, arXiv preprint arXiv:2003.09861.
- [15] K. S. Kim, K. Ejima, Y. Ito, S. Iwanami, H. Ohashi, Y. Koizumi, Y. Asai, S. Nakaoka, K. Watashi, R. N. Thompson, et al., Modelling SARS-CoV-2 Dynamics: Implications for Therapy, medRxiv.
- [16] P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden, A. S. Perelson, Kinetics of influenza A virus infection in humans, Journal of virology 80 (15) (2006) 7590–7599.
- [17] E. A. Hernandez-Vargas, E. Wilk, L. Canini, F. Toapanta, S. Binder, A. Uvarovskii, T. Ross, C. A. Guzman, A. Perelson, M. Meyer-Hermann, Effects of Aging on Influenza Virus Infection Dynamics, Journal of virology 88. doi:10.1128/JVI.03644-13.

- [18] V. Nguyen, S. Binder, A. Boianelli, M. Meyer-Hermann, E. A. Hernandez-Vargas, Ebola Virus Infection Modelling and Identifiability Problems, Frontiers in microbiology 6. doi:10.3389/fmicb.2015.00257.
- [19] L. Rong, A. Perelson, Modeling HIV persistence, the latent reservoir, and viral blips, Journal of theoretical biology 260 (2009) 308-31. doi:10.1016/j.jtbi.2009.06.011.
- [20] A. S. Perelson, R. M. Ribeiro, Modeling the within-host dynamics of HIV infection, BMC biology 11 (1) (2013) 96.
- [21] F. Graw, A. Perelson, Modeling viral spread, Annual Review of Virology 3. doi:10.1146/annurev-virology-110615-042249.
- [22] R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, et al., Virological assessment of hospitalized patients with COVID-2019, Nature 581 (7809) (2020) 465–469.
- [23] P. Abuin, A. Anderson, A. Ferramosca, E. A. Hernandez-Vargas, A. H. Gonzalez, Characterization of SARS-CoV-2 Dynamics in the Host, Annual Reviews in Control.
- [24] E. A. Hernandez-Vargas, Modeling and Control of Infectious Diseases in the Host: With MATLAB and R, Academic Press, 2019.
- [25] S. M. Ciupe, J. M. Heffernan, In-host modeling, Infectious Disease Modelling 2 (2) (2017) 188–202.
- [26] A. S. Perelson, D. E. Kirschner, R. De Boer, Dynamics of HIV infection of CD4+ T cells, Mathematical biosciences 114 (1) (1993) 81–125.
- [27] M. Legrand, E. Comets, G. Aymard, R. Tubiana, C. Katlama, B. Diquet, An in vivo pharmacokinetic/pharmacodynamic model for antiretroviral combination, HIV Clinical trials 4 (3) (2003) 170– 183.
- [28] E. W. Larson, J. W. Dominik, A. H. Rowberg, G. A. Higbee, Influenza virus population dynamics in the respiratory tract of experimentally infected mice., Infection and immunity 13 (2) (1976) 438–447.
- [29] A. M. Smith, A. S. Perelson, Influenza A virus infection kinetics: quantitative data and models, Wiley Interdisciplinary Reviews: Systems Biology and Medicine 3 (4) (2011) 429–445.
- [30] G. Hernandez-Mejia, A. Y. Alanis, M. Hernandez-Gonzalez, R. Findeisen, E. A. Hernandez-Vargas, Passivity-based inverse optimal impulsive control for Influenza treatment in the host, IEEE Transactions on Control Systems Technology.
- [31] R. Nikin-Beers, S. M. Ciupe, The role of antibody in enhancing dengue virus infection, Mathematical biosciences 263 (2015) 83–92.
- [32] R. Nikin-Beers, S. M. Ciupe, Modelling original antigenic sin in dengue viral infection, Mathematical medicine and biology: a journal of the IMA 35 (2) (2018) 257–272.
- [33] H. Ikeda, S. Nakaoka, R. J. de Boer, S. Morita, N. Misawa, Y. Koyanagi, K. Aihara, K. Sato, S. Iwami, Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model, Retrovirology 13 (1) (2016) 23.
- [34] M. Nowak, R. M. May, Virus dynamics: mathematical principles of immunology and virology, Oxford University Press, UK, 2000.
- [35] H. Dahari, A. Lo, R. M. Ribeiro, A. S. Perelson, Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy, Journal of theoretical biology 247 (2) (2007) 371–381.
- [36] S. Jomah, S. M. B. Asdaq, M. J. Al-Yamani, Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review, Journal of Infection and Public Health.

- [37] C. Liu, Q. Zhou, Y. Li, L. V. Garner, S. P. Watkins, L. J. Carter, J. Smoot, A. C. Gregg, A. D. Daniels, S. Jervey, et al., Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases (2020).
- [38] M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro, Cell research 30 (3) (2020) 269–271.
- [39] H. M. Dobrovolny, Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2, Virology.
- [40] J.-M. Vergnaud, I.-D. Rosca, Assessing bioavailablility of drug delivery systems: mathematical modeling, CRC press, 2005.
- [41] C. Hadjichrysanthou, E. Cauët, E. Lawrence, C. Vegvari, F. De Wolf, R. M. Anderson, Understanding the within-host dynamics of influenza A virus: from theory to clinical implications, Journal of The Royal Society Interface 13 (119) (2016) 20160289.
- [42] H. M. Dobrovolny, R. Gieschke, B. E. Davies, N. L. Jumbe, C. A. Beauchemin, Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study, Journal of theoretical biology 269 (1) (2011) 234–244.
- [43] R. Storn, K. Price, Differential evolution-a simple efficient adaptive scheme for global optimization, Tech. rep., Tech. Rep. TR-95-012, International Computer Science Institute, Berkeley ... (1995).
- [44] C. E. Torres-Cerna, A. Y. Alanis, I. Poblete-Castro, M. Bermejo-Jambrina, E. A. Hernandez-Vargas, A comparative study of differential evolution algorithms for parameter fitting procedures, in: 2016 IEEE Congress on Evolutionary Computation (CEC), IEEE, 2016, pp. 4662–4666.
- [45] A. Gupta, M. V. Madhavan, K. Sehgal, N. Nair, S. Mahajan, T. S. Sehrawat, B. Bikdeli, N. Ahluwalia, J. C. Ausiello, E. Y. Wan, et al., Extrapulmonary manifestations of COVID-19, Nature medicine 26 (7) (2020) 1017–1032.
- [46] E. A. Hernandez-Vargas, R. H. Middleton, Modeling the three stages in HIV infection, Journal of theoretical biology 320 (2013) 33–40.
- [47] X. He, E. H. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, et al., Temporal dynamics in viral shedding and transmissibility of COVID-19, Nature medicine 26 (5) (2020) 672–675.
- [48] B. N. Williamson, F. Feldmann, B. Schwarz, K. Meade-White, D. P. Porter, J. Schulz, N. Van Doremalen, I. Leighton, C. K. Yinda, L. Pérez-Pérez, et al., Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, BioRxiv.
- [49] V. J. Munster, F. Feldmann, B. N. Williamson, N. van Doremalen, L. Pérez-Pérez, J. Schulz, K. Meade-White, A. Okumura, J. Callison, B. Brumbaugh, et al., Respiratory disease in rhesus macaques inoculated with SARS-CoV-2, Nature (2020) 1–5.
- [50] A. Raue, C. Kreutz, T. Maiwald, J. Bachmann, M. Schilling, U. Klingmüller, J. Timmer, Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood, Bioinformatics 25 (15) (2009) 1923–1929.
- [51] B. Zhou, J. She, Y. Wang, X. Ma, The duration of viral shedding of discharged patients with severe COVID-19, Clinical Infectious Diseases.
- [52] D. S. Callaway, A. S. Perelson, HIV-1 infection and low steady state viral loads, Bulletin of mathematical biology 64 (1) (2002) 29–64.
- [53] Y. Huang, S. L. Rosenkranz, H. Wu, Modeling hiv dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity, Mathematical biosciences 184 (2) (2003) 165–186.

- [54] W. S. T. Consortium, Repurposed antiviral drugs for COVID-19 interim WHO SOLIDARITY trial results, New England Journal of Medicine.
- [55] A. Goyal, E. F. Cardozo-Ojeda, J. T. Schiffer, Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response, medRxiv.
- [56] P. Cao, J. M. McCaw, The mechanisms for within-host influenza virus control affect model-based assessment and prediction of antiviral treatment, Viruses 9 (8) (2017) 197.
- [57] J. Wu, W. Li, X. Shi, Z. Chen, B. Jiang, J. Liu, D. Wang, C. Liu, Y. Meng, L. Cui, et al., Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19), Journal of internal medicine.
- [58] S. Kaushal, A. S. Rajput, S. Bhattacharya, M. Vidyasagar, A. Kumar, M. K. Prakash, S. Ansumali, Estimating Hidden Asymptomatics, Herd Immunity Threshold and Lockdown Effects using a COVID-19 Specific Model, arXiv preprint arXiv:2006.00045.